



★ Providing tomorrow's necessities

## **ARIANNE PHOSPHATE INC.**

### **CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2025 AND 2024**

(IN CANADIAN DOLLARS)



## Independent Auditor's Report

---

Raymond Chabot  
Grant Thornton LLP  
Suite 2000  
600 De La Gauchetière Street West  
Montréal, Quebec  
H3B 4L8

T 514-878-2691

To the Shareholders of  
Arianne Phosphate Inc.

### Opinion

We have audited the consolidated financial statements of Arianne Phosphate Inc. (hereafter "the Company"), which comprise the consolidated statements of financial position as at December 31, 2025 and 2024, and the consolidated statements of income (loss) and comprehensive income (loss), the consolidated statements of changes in equity and the consolidated statements of cash flows for the years then ended, and notes to the consolidated financial statements, including material accounting policy information.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2025 and 2024, and its financial performance and its cash flows for the years then ended in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (hereafter "IFRS Accounting Standards").

### Basis for opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditor's responsibilities for the audit of the consolidated financial statements" section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Material uncertainty related to going concern

We draw attention to Note 1 to the consolidated financial statements, which indicates the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

**Key audit matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Except for the matter described in the "Material uncertainty related to going concern" section, we have determined that there are no other key audit matters to communicate in our report.

**Information other than the consolidated financial statements and the auditor's report thereon**

Management is responsible for the other information. The other information comprises the information included in Management's Discussion and Analysis.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

We obtained Management's Discussion and Analysis prior to the date of this auditor's report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact in this auditor's report. We have nothing to report in this regard.

**Responsibilities of management and those charged with governance for the consolidated financial statements**

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with IFRS Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

**Auditor's responsibilities for the audit of the consolidated financial statements**

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable

assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control;
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern;
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation;
- Plan and perform the group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the group as a basis for forming an opinion on the group financial statements. We are responsible for the direction, supervision and review of the audit work performed for purposes of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are, therefore, the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this independent auditor's report is Karine Desrochers.

*Raymond Chabot Grant Thornton LLP<sup>1</sup>*

Montréal  
April 27, 2026

---

<sup>1</sup> CPA auditor, public accountancy permit no. A127023

**ARIANNE PHOSPHATE INC.**  
**CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**  
**AS AT DECEMBER 31**  
(IN CANADIAN DOLLARS)

	<b>2025</b>	<b>2024</b>
	\$	\$
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Cash and cash equivalents (Note 5)	2,084,216	4,479,865
Receivables and other current assets	213,260	159,260
Sales taxes receivable	50,563	73,998
Deferred transaction costs	21,227	-
	<b>2,369,266</b>	<b>4,713,123</b>
<b>NON-CURRENT ASSETS</b>		
Investment property – Outfitters (Note 6)	174,087	192,601
Right-of-use assets (Note 7)	70,695	94,260
Property and equipment (Note 8)	63,242,279	63,114,153
<b>TOTAL ASSETS</b>	<b>65,856,327</b>	<b>68,114,137</b>
<b>LIABILITIES</b>		
<b>CURRENT LIABILITIES</b>		
Accounts payable and accrued liabilities	246,358	254,863
Lease liabilities (Note 9)	26,781	23,218
Convertible debenture and embedded derivatives (Note 11)	4,140,100	3,332,912
Credit line and embedded derivatives (Note 10)	25,952,462	1,677,813
	<b>30,365,701</b>	<b>5,288,806</b>
<b>NON-CURRENT LIABILITIES</b>		
Credit line and embedded derivatives (Note 10)	294,623	29,543,545
Lease liabilities (Note 9)	53,839	84,426
Deferred income taxes (Note 15)	3,702,929	3,702,929
<b>TOTAL LIABILITIES</b>	<b>34,417,092</b>	<b>38,619,706</b>
<b>EQUITY</b>		
Capital stock (Note 14)	93,934,776	92,256,963
Warrants (Note 14)	8,468,851	8,416,000
Contributed surplus	18,620,461	18,437,707
Deficit	(89,584,853)	(89,616,239)
<b>TOTAL EQUITY</b>	<b>31,439,235</b>	<b>29,494,431</b>
<b>TOTAL LIABILITIES AND EQUITY</b>	<b>65,856,327</b>	<b>68,114,137</b>

**GOING CONCERN (NOTE 1)**  
**SUBSEQUENT EVENTS (NOTE 21)**

*The accompanying Notes are an integral part of these consolidated financial statements.*

APPROVED ON BEHALF OF THE BOARD:

(s) Siva J. Pillay, Director

(s) Marco Gagnon, Director

# ARIANNE PHOSPHATE INC.

## CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(IN CANADIAN DOLLARS)

	<b>2025</b>	<b>2024</b>
	\$	\$
<b>EXPENSES</b>		
Salaries and benefits	753,143	740,076
Share-based compensation (Note 14)	182,754	284,361
Professional and consultant fees	143,157	140,032
Management fees	29,980	-
Registration and listing fees	105,369	99,940
Annual Meeting fees	24,330	33,601
Communications and investors relation	154,957	209,496
Promotion, representation, and travel	80,551	69,298
Direct application projects and prefeasibility study	739,013	833,153
Insurance	67,999	68,956
Rent and office expenses	67,081	67,975
Depreciation of property and equipment and right-of-use assets	27,540	37,913
Bank charges	2,046	1,779
Grants	-	(4,288)
<b>OPERATING LOSS</b>	<b>2,377,920</b>	<b>2,582,292</b>
<b>OTHER EXPENSES (INCOME)</b>		
Finance costs (income) (Note 12)	(2,532,231)	8,312,168
Foreign exchange loss	477	8,905
Net loss of investment property – Outfitter (Note 6)	111,657	91,869
	(2,420,097)	8,412,942
<b>INCOME (LOSS) BEFORE INCOME TAXES</b>	<b>42,177</b>	<b>(10,995,234)</b>
Deferred income taxes recovery	-	4,515
<b>NET AND COMPREHENSIVE INCOME (LOSS)</b>	<b>42,177</b>	<b>(10,990,719)</b>
<b>BASIC AND DILUTED EARNINGS (LOSS) PER SHARE</b>	0.00	(0.05)
<b>WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING</b>	211,045,731	201,361,668

*The accompanying Notes are an integral part of these consolidated financial statements.*

**ARIANNE PHOSPHATE INC.**  
**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 and 2024**

(IN CANADIAN DOLLARS, EXCEPT FOR NUMBER OF SHARES)

	<b>CAPITAL STOCK</b>	<b>CONTRIBUTED</b>			<b>DEFICIT</b>	<b>TOTAL EQUITY</b>
	<b>CAPITAL STOCK</b>	<b>WARRANTS</b>	<b>SURPLUS</b>			
	common shares	\$	\$	\$	\$	\$
<b>BALANCE AS AT JANUARY 1, 2025</b>	202,890,210	92,256,963	8,416,000	18,437,707	(89,616,239)	29,494,431
Net and comprehensive income	-	-	-	-	42,177	42,177
Share-based compensation (Note 14)	-	-	-	182,754	-	182,754
Warrants issued (Note 14)	-	-	52,851	-	-	52,851
Debt conversion (Note 10)	10,824,601	1,677,813	-	-	-	1,677,813
Share issuance expense	-	-	-	-	(10,791)	(10,791)
<b>BALANCE AS AT DECEMBER 31, 2025</b>	<b>213,714,811</b>	<b>93,934,776</b>	<b>8,468,851</b>	<b>18,620,461</b>	<b>(89,584,853)</b>	<b>31,439,235</b>
<b>BALANCE AS AT JANUARY 1, 2024</b>	196,809,271	90,615,110	8,624,673	17,944,673	(78,614,702)	38,569,754
Net and comprehensive loss	-	-	-	-	(10,990,719)	(10,990,719)
Share-based compensation (Note 14)	-	-	-	284,361	-	284,361
Warrants expired (Note 14)	-	-	(208,673)	208,673	-	-
Debt conversion (Note 10)	6,080,939	1,641,853	-	-	-	1,641,853
Share issuance expense	-	-	-	-	(10,818)	(10,818)
<b>BALANCE AS AT DECEMBER 31, 2024</b>	<b>202,890,210</b>	<b>92,256,963</b>	<b>8,416,000</b>	<b>18,437,707</b>	<b>(89,616,239)</b>	<b>29,494,431</b>

*The accompanying Notes are an integral part of these consolidated financial statements*

**ARIANNE PHOSPHATE INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 and 2024**  
(IN CANADIAN DOLLARS)

	<b>2025</b>	<b>2024</b>
	\$	\$
<b>OPERATING ACTIVITIES</b>		
Net income (loss)	42,177	(10,990,719)
Adjustments for:		
Share-based payments	182,754	284,361
Depreciation – Investment property - Outfitters	21,014	20,763
Depreciation – Property and equipment and right-of-use assets	27,540	37,913
Finance costs	(2,433,520)	8,414,503
Deferred income taxes expense (recovery)	-	(9,092)
Changes in non-cash working capital items		
Receivables and other current assets	(54,000)	17,820
Sales taxes receivable	23,435	(33,746)
Accounts payable and accrued liabilities	(25,172)	47,374
<b>CASH FLOWS USED IN OPERATING ACTIVITIES</b>	<b>(2,215,772)</b>	<b>(2,210,823)</b>
<b>INVESTING ACTIVITIES</b>		
Proceeds from tax credits related to resources and mining tax credits	-	19,486
Acquisition of property and equipment	(136,661)	(166,822)
Acquisition of property and equipment - Outfitter	(2,500)	(19,603)
<b>CASH FLOWS USED IN INVESTING ACTIVITIES</b>	<b>(139,161)</b>	<b>(166,939)</b>
<b>FINANCING ACTIVITIES</b>		
Share issuance expenses	(10,791)	(10,818)
Repayment of lease liabilities	(29,925)	(34,385)
Proceeds from convertible debenture	-	3,808,269
Issuance costs – convertible debenture	-	(150,942)
<b>CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES</b>	<b>(40,716)</b>	<b>3,612,124</b>
<b>NET CHANGE IN CASH AND CASH EQUIVALENTS</b>	<b>(2,395,649)</b>	<b>1,234,362</b>
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	4,479,865	3,245,503
<b>CASH AND CASH EQUIVALENTS, END OF YEAR</b>	<b>2,084,216</b>	<b>4,479,865</b>
<b>SUPPLEMENTARY CASH FLOW INFORMATION</b>		
Interest received	98,711	111,252
Interest paid	2,901	9,955
Interest on credit line paid in shares	1,677,813	1,641,853
Acquisition of property and equipment not yet paid	809	5,369

*The accompanying Notes are an integral part of these consolidated financial statements.*

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

---

**1. STATUTE OF INCORPORATION, NATURE OF ACTIVITIES AND GOING CONCERN**

Arianne Phosphate Inc. ("the Company") was incorporated under Part IA of the *Companies Act* (Quebec) and was continued under the *Business Corporations Act* (Quebec) (QBCA). The Company is engaged in the development of its Lac à Paul phosphate property located in Quebec, Canada. The Company has a Regulation 43-101 compliant technical report for its mineral reserve and resource estimate and for a feasibility study on the Lac à Paul property. In October 2018, management determined that the technical feasibility and commercial viability of the Lac à Paul property had been established and accordingly, the development phase for the Lac à Paul property has commenced.

The Company's shares are listed on the TSX Venture Exchange (symbol DAN), on the Frankfurt exchange (symbol JE9N) and on the OTCQB Market (OTCQB) (symbol DRRSF). The registered office of the Company is located at 901 Talbot boulevard, Suite 302, Chicoutimi, Quebec, Canada G7H 6N7.

Although management has taken steps to verify titles of mining properties in which the Company has an interest, in accordance with industry standards for the current stage of exploration of such properties, these procedures do not guarantee the Company's title. Property title may be subject to unregistered prior agreements and non-compliant with regulatory requirements.

These consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business as they come due. In assessing whether the going concern assumption is appropriate, management considers all available information about the future, which is at least, but not limited to, 12 months from the end of the reporting period. For the year ended December 31, 2025, the Company recorded a net income of \$42,177 (2024 – loss of \$10,990,719) and has an accumulated deficit of \$89,584,853 as at December 31, 2025 (2024 – \$89,616,239). In addition to ongoing working capital requirements, the Company must secure sufficient funding to meet its obligations and pay general and administration costs.

As at December 31, 2025, the Company had a negative working capital of \$27,996,435 (negative working capital of \$575,683 in 2024). The working capital includes the convertible debenture of \$4,140,100 as at December 31, 2025 even if the repayment is due in 2027 because the convertible option is a derivative and not an equity item (Note 11). It also includes the credit line as the maturity, before refinancing, was March 2026 and, per IAS 1.72 (Note 21). Management estimates that the working capital will not be sufficient to meet the Company's obligations and budgeted operating and development expenditures for the next 12 months. These circumstances are indicative of the existence of material uncertainties that may cast significant doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern. The Company will need to secure financing for 2026.

Any funding shortfall may be met in the future in a number of ways including, but not limited to, the issuance of new equity, debt financing or securing capital from potential partners. While management has been successful in securing financing in the past, there can be no assurance that it will be able to do so in the future or that these sources of funding or initiatives will be available to the Company or that they will be available on terms which are acceptable to the Company. If management is unable to obtain new funding, the Company may be unable to continue its operations, and amounts realized for assets might be less than amounts reflected in the consolidated financial statements.

These consolidated financial statements do not reflect the adjustments to the carrying values of assets and

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

---

liabilities, expenses and financial position classifications that would be necessary if the going concern assumption was not appropriate. These adjustments could be material.

**2. SUMMARY OF MATERIAL ACCOUNTING POLICIES**

The material accounting policies used in the preparation of these consolidated financial statements are described below.

**BASIS OF PREPARATION**

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS Accounting Standards). The Company has consistently applied the accounting policies used in the preparation of its IFRS consolidated financial statements, including the comparative figures. The Board of Directors approved the consolidated financial statements on April 27, 2026.

**BASIS OF MEASUREMENT**

These consolidated financial statements have been prepared on a historical cost basis.

**BASIS OF CONSOLIDATION**

These consolidated financial statements incorporate the accounts of the Company and accounts of entities it controls, including Arianne Logistics Inc. and 9252-5880 Québec Inc., which are all wholly owned subsidiaries.

Subsidiaries are entities that the Company controls either when it is exposed, or has rights, to variable returns from its involvement with the entities and has the ability to affect those returns through its power over the entities. The amounts presented in the consolidated financial statements of subsidiaries have been adjusted, if necessary, so that they meet the accounting policies adopted by the Company.

Profit or loss or other comprehensive income (loss) of subsidiaries set up, acquired, or sold during the year are recorded from the actual date of acquisition or until the effective date of the sale, if any. All intercompany transactions, balances, income, and expenses are eliminated at consolidation.

**FUNCTIONAL AND PRESENTATION CURRENCY**

The presentation currency and the functional currency of all operations of the Company and its subsidiaries is the Canadian dollar, since it represents the currency of the primary economic environment in which the Company and its subsidiaries operate.

Transactions in foreign currencies are translated at the exchange rates prevailing at the time they are incurred. At each closing date, monetary assets and liabilities denominated in foreign currencies are converted at the closing exchange rate. Revenue, expenses and non-monetary assets and liabilities denominated in foreign currencies are recorded at the rate of exchange prevailing at the transaction date. Exchange differences are recorded in the consolidated statements of income (loss) and comprehensive income (loss) for the year.

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

---

**FINANCIAL INSTRUMENTS**

Financial assets and financial liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets had expired or been transferred and the Company had transferred substantially all risks and rewards of ownership. Financial assets and financial liabilities are offset, and the net amount is reported in the consolidated statements of financial position, when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously.

TRANSACTION COSTS

Transaction costs related to financial assets are added to the carrying value of the asset, and transaction costs related to financial liabilities at amortized cost are netted against the carrying value of the liability. They are then recognized over the expected life of the instrument using the effective interest method.

Transaction costs include fees and commissions paid to agents, advisers, brokers and dealers, levies by regulatory agencies and securities exchanges, and transfer taxes and duties. Transaction costs do not include debt premiums or discounts, financing costs or internal administrative or holding costs.

EFFECTIVE INTEREST METHOD

The effective interest method is a method of calculating the amortized cost of a financial asset/liability and of allocating interest income/expense over the relevant period. The effective interest rate is the rate that discounts estimated future cash flows (including transaction costs) through the expected life of the financial asset/liability, or, if appropriate, a shorter period.

MODIFICATIONS/AMENDMENTS TO LONG-TERM DEBT

When a financial liability measured at amortized cost is modified without resulting in derecognition, a gain or loss is recognized in profit or loss. The gain or loss is calculated as the difference between the original contractual cash flows and the modified cash flows discounted at the original effective interest rate.

MEASUREMENT

At initial recognition, the Company measures a financial asset or financial liability at its fair value plus or minus, in the case of a financial asset or financial liability not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition or issue of the financial asset or financial liability. Transaction costs of financial assets or financial liabilities carried at FVPL are expensed in the consolidated statements of income (loss) and comprehensive income (loss). Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest. Measurement in subsequent periods depends on the classification of the financial instrument. The Company has classified its financial instruments in the following categories depending on the purpose for which the instruments were acquired and their characteristics.

Financial assets

Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortized cost. Interest income from these financial

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition is recognized directly in profit or loss and presented in other gains/losses. Impairment losses are presented as separate line item in the consolidated statement of income (loss) and comprehensive income (loss).

Financial liabilities

Financial liabilities are subsequently measured at amortized cost using the effective interest method, except for financial liabilities at FVPL. Such liabilities, including derivatives that are liabilities, shall be subsequently measured at fair value.

EMBEDDED DERIVATIVES

An embedded derivative is a component of a hybrid contract that also includes a non-derivative host, with the effect that some of the cash flows of the combined instrument vary in a way similar to a stand-alone derivative. If a hybrid contract contains a host that is a financial asset, the entire hybrid contract is measured at fair value through net income (loss). If a hybrid contract contains a host that is not a financial asset, embedded derivatives are recorded at fair value separately from the host contract when their economic characteristics and risks are not clearly and closely related to those of the host contract. Subsequent changes in fair value are recorded in the consolidated statements of income (loss).

The credit line of the Company and the convertible debenture are hybrid financial instruments that contains embedded derivatives (Note 10, 11). The hybrid financial instrument is recognized as a liability, with the initial carrying value of the credit line (host) and convertible debenture (host), each being the residual amount of the proceeds after separating the derivative components, which is recognized at fair value. Any directly attributable transaction costs are entirely allocated to the host. Subsequent to initial recognition, the host component of the hybrid financial instrument is measured at amortized cost using the effective interest method. The derivative components of the hybrid financial instrument is measured at fair value through net income (loss). Subsequent changes in fair value are recorded in the consolidated statements of income (loss) and comprehensive income (loss).

The Company has classified its financial instruments as follows:

CATEGORY	FINANCIAL INSTRUMENT
Financial assets at amortized costs	Cash and cash equivalents Receivables and other current assets
Financial assets at fair value through net income (loss)	Embedded derivative – prepayment option Embedded derivative – interest conversion option - Credit line
Financial liabilities at amortized costs	Accounts payable and accrued liabilities Host - Credit line Host – Convertible debenture
Financial liabilities at fair value through net income (loss)	Embedded derivative – supplemental warrants - Credit line Embedded derivatives – Convertible debenture

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

**INVESTMENT PROPERTY – OUTFITTER**

Investment property is a property (land or a building – or part of a building – or both) held to earn rental income or for capital appreciation or both, rather than for (a) use in the production or supply of goods or services or for administrative purposes; or (b) sale in the ordinary course of business. An investment property is measured initially at cost. Transaction costs are included in the initial measurement. The Company uses the cost model as its accounting policy on its investment property. After recognition, an investment property is carried at its cost less any accumulated depreciation and any accumulated impairment losses.

Each property and equipment part included in investment property – Outfitters is depreciated separately over its useful life.

Rental income and direct operating expenses arising from investment property – Outfitters, including depreciation of property and equipment, are recognized in the consolidated statements of income (loss) as “net loss of investment property – Outfitter”.

Depreciation is calculated to amortize the cost of the property and equipment comprised in the investment property – outfitter over their estimated useful lives using the straight-line method on the basis of the following periods:

CATEGORY	RATES
Buildings	25 years
Leasehold improvements	Lease term
Computer equipment	4 years
Equipment and furniture	8 years

**PROPERTY AND EQUIPMENT**

Property and equipment (“P&E”) are accounted for at historical cost less any accumulated depreciation charge and impairment losses. Historical cost includes expenditures that are directly attributable to the acquisition of the asset. Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost can be measured reliably.

Depreciation is calculated to amortize the cost of the property and equipment over their estimated useful lives using the straight-line method on the basis of the following periods:

CATEGORY	RATES
Tools and equipment	10 years
Leasehold improvements	Lease term
Computer equipment	4 years
Rolling equipment	8 years
Mineral property under development	Units of production

The residual value, depreciation method and the useful life of each asset are reviewed at least at each financial year-end. Gains or losses on disposal of property and equipment are determined by comparing the net proceeds with the net carrying amount of the asset and are included in the consolidated statement of income (loss) and comprehensive income (loss).

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

---

Upon transfer of exploration and evaluation assets and mining properties to mineral property under development within property and equipment, all subsequent expenditures on the construction, installation or completion of infrastructure facilities are capitalized within mineral property under development. After production starts, all assets included in mineral property under development within property and equipment are transferred to producing mines assets within property and equipment. When commercial production commences, these costs will be charged to operations on a unit of production method based on proven and probable reserves.

Capitalized costs, including certain mine development and construction costs, are not depreciated until the time at which the related mining property has reached a pre-determined level of operating capacity intended by management. Costs incurred prior to this point, including depreciation of related P&E, are capitalized. Upon completion of construction, mining property under development are amortized on a unit of production basis, which is measured by the portion of the mine's economically recoverable and proven ore reserves produced during the period. Impairment is tested in the same way as other non-financial assets.

**LEASES**

The Company leases offices and equipment. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. Leases are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the Company. Each lease payment is allocated between the lease liabilities and finance cost. The finance cost is charged to profit or loss over the lease period to produce a constant periodic rate of interest on the remaining balance of the lease liabilities for each period. The weighted average incremental borrowing rate applied to the lease liabilities is 8.0%. Assets and liabilities arising from leases are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments:

- fixed payments, less any lease incentives receivable;
- variable lease payment that are based on an index or a rate;
- amounts expected to be payable by the lessee under residual value guarantees;
- the exercise price of a purchase option if the lessee is reasonably certain to exercise that option;
- payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.

**RIGHT-OF-USE ASSETS**

The Company recognizes right-of-use assets at the commencement date of the lease. Right-of-use assets are measured at cost, less any accumulated depreciation, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term.

**LEASE LIABILITIES**

At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs.

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

---

In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is reduced with the lease payments principal made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset.

**SHORT-TERM LEASES**

The Company applies the short-term lease recognition exemption to all its short-term leases (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). Lease payments on short-term leases are expensed on a straight-line basis over the lease term.

**IMPAIRMENT OF NON-FINANCIAL ASSETS**

Property and equipment, right-of-use assets and investment property – Outfitters are reviewed for impairment if there is any indication that the carrying amount may not be recoverable. If any such indication is present, the recoverable amount of the asset is estimated to determine whether impairment exists. Where the asset does not generate cash flows that are independent from other assets, the Company estimates the recoverable amount of the asset group to which the asset belongs.

An asset's recoverable amount is the higher of fair value less costs to dispose of and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value, using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset or asset group is estimated to be less than its carrying amount, the carrying amount is reduced to the recoverable amount. Impairment is recognized immediately in the consolidated statements of income (loss). Where an impairment subsequently reverses, the carrying amount is increased to the revised estimate of recoverable amount but only to the extent that this does not exceed the carrying value that would have been determined if no impairment had previously been recognized. A reversal is recognized as a reduction in the impairment charge for the period.

**SHARE-BASED PAYMENT TRANSACTIONS**

The fair value of stock options granted to employees is recognized as an expense or capitalized to mineral property under development over the vesting period with a corresponding increase in the contributed surplus. An individual is classified as an employee when the individual is an employee for legal or tax purposes (direct employee) or provides services like those performed by a direct employee, including directors of the Company.

The fair value is measured at the grant date and recognized over the period during which the options vest. The fair value of the options granted is measured using the Black-Scholes pricing model, considering the terms and conditions upon which the options were granted. At each consolidated statement of financial position reporting date, the amount recognized as an expense is adjusted to reflect the actual number of share options that are expected to vest.

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

---

**EQUITY-SETTLED SHARE-BASED PAYMENT TRANSACTIONS**

For transactions with parties other than employees, the Company measures the goods or services received, and the corresponding increase in equity, directly, at the fair value of the goods or services received, unless that fair value cannot be estimated reliably. When the Company cannot estimate reliably the fair value of the goods or services received, it measures their value, and the corresponding increase in equity, indirectly, by reference to the fair value of the equity instruments granted.

All equity-settled share-based compensation (except brokers options) are ultimately recognized as an expense in the consolidated statements of income (loss) with a corresponding credit to contributed surplus, in equity. Equity-settled share-based compensation to brokers, in respect of an equity or debt financing, are recognized respectively as issuance cost of the equity instruments with a corresponding credit to deficit or against the financial liabilities.

**WARRANTS**

As part of its financing activities, the Company may grant warrants. Each warrant entitles its holder to purchase a determined number of shares at a price determined at grant for a certain period. Proceeds from unit placements are allocated between shares and warrants issued using the relative fair value method on a pro rata basis. The Company uses the Black-Scholes pricing model to determine the fair value of warrants issued.

**SHARE ISSUANCE EXPENSES**

Share issuance expenses are recorded as an increase of the deficit in the year in which they are incurred.

**SEGMENT DISCLOSURES**

The Company currently operates in a single segment: the development of the Lac à Paul Phosphate property. All the Company's activities are conducted in Canada.

**3. ACCOUNTING STANDARDS ADOPTED AND ACCOUNTING STANDARDS ISSUED BUT NOT YET EFFECTIVE**

**NEW ACCOUNTING STANDARDS ISSUED BUT NOT YET EFFECTIVE**

*AMENDMENTS TO IFRS 18, PRESENTATION AND DISCLOSURE IN FINANCIAL STATEMENTS*

On April 9, 2024, the IASB issued IFRS 18 to improve reporting of financial performance. The new standard replaces IAS 1 *Presentation of Financial Statements*. It carries forward many requirements from IAS 1 unchanged. IFRS 18 applies for annual reporting periods beginning on or after January 1, 2027, with earlier application permitted. The new Accounting Standard introduces significant changes to the structure of income statements and introduces new principles for aggregation and disaggregation of information, including:

- presentation of two new defined subtotals in the statement of profit or loss: (1) Operating profit; and (2) Profit before financing and income taxes
- required disclosures in the notes to the financial statements of management-defined performance measures.

The impact of adoption of the amendments has not yet been determined by the Company.

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

---

AMENDMENTS TO THE CLASSIFICATION AND MEASUREMENT OF FINANCIAL INSTRUMENTS (AMENDMENTS TO IFRS 9 AND IFRS 7)

In May 2024, the IASB issued Amendments to IFRS 9 and IFRS 7, Amendments to the Classification and Measurement of Financial Instruments (the Amendments). The Amendments include:

- A clarification that a financial liability is derecognised on the settlement date and the introduction of an accounting policy choice to derecognise financial liabilities settled using an electronic payment system before the settlement date if specific conditions are met. If an entity elects to apply this accounting policy, it must do so for all settlements made through the same electronic payment system.
- Additional guidance on how an entity should assess whether contractual cash flows of a financial asset are consistent with a basic lending arrangement. This is intended to assist an entity to apply the requirements for assessing contractual cash flow characteristics to financial assets with features linked to environmental, social and governance (ESG) concerns.
- Clarifications on what constitute non-recourse features and what are the characteristics of contractually linked instruments
- Additional disclosure requirements for investments in equity instruments designated at fair value through other comprehensive income (OCI) and the introduction of disclosure of the contractual terms that could change the timing or amount of contractual cash flows on the occurrence (or non-occurrence) of a contingent event that does not relate directly to changes in a basic lending risks and costs.

The amendments are effective for annual reporting periods beginning on or after 1 January 2026 with earlier application permitted. If an entity elects to apply these amendments for an earlier period, it is required to either:

- apply all the amendments at the same time and disclose that fact or
- apply only the amendments to the classification of financial assets for that earlier period and disclose that fact.

The amendments are required to be applied retrospectively, in accordance with IAS 8, with specific exceptions. The Company does not anticipate that the amendments will have a material effect on the Company's financial statements.

#### **4. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS**

The preparation of consolidated financial statements in accordance with IFRS Accounting Standards requires management to make estimates and assumptions that affect the application of accounting policies as well as the carrying amounts of assets, liabilities, revenues, and expenses. Actual results may differ from those estimates.

The estimates and underlying assumptions are reviewed regularly. Any revisions to accounting estimates are recognized in the period during which the estimates are revised and in future periods affected by these revisions.

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

---

**CRITICAL JUDGMENTS IN APPLYING ACCOUNTING POLICIES**

LIQUIDITY RISK/GOING CONCERN

The assessment of the Company's ability to execute its strategy by funding future working capital and developing its Lac à Paul phosphate property involves judgment. Estimates and assumptions are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

EXPECTED CASH FLOWS OF THE CREDIT LINE

The Company exercises critical judgement in estimating the timing of the expected cash flows from the production fees buy-back included in the credit line, as they are to be included in the amortized cost of the host contract. Assumptions are continually reevaluated and are based on expectations of future events that are believed to be reasonable under the circumstances.

**CRITICAL JUDGMENTS IN APPLYING ACCOUNTING ESTIMATES**

FAIR VALUE OF EMBEDDED DERIVATIVES

The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. This involves developing estimates and assumptions that are mainly based on market conditions existing at the end of each reporting period and a probability of occurrence for each scenario considered. Management based its assumptions on observable data as far as possible, but this is not always available. In that case, management uses the best information available.

IMPAIRMENT INDICATORS OF NON-FINANCIAL ASSETS

Non-financial assets are reviewed for an indication of impairment at each consolidated statement of financial position date. This determination requires significant judgment. Factors which could trigger an impairment review include, but are not limited to, significant negative industry or economic trends, interruptions in exploration and evaluation activities, a significant change in the activities of the Company and significant drop in commodity prices. Non-financial assets are reviewed for an indication of impairment at each consolidated statement of financial position date. This determination requires significant judgment.

IMPAIRMENT OF NON-FINANCIAL ASSETS

The Company's recoverable amount measurements with respect to the carrying amount of non-financial assets are based on numerous assumptions and may differ significantly from actual recoverable amounts. The recoverable amounts are based, in part, on certain factors that may be partially or totally outside of the Company's control. The fair value of non-financial assets requires the use of estimates and assumptions for recoverable production, long-term purified phosphoric acid and green acid prices, discount rates, operating costs, capex costs and considered orientations of the project by the management. These assumptions are, by their very nature, subject to interpretation and uncertainty. This evaluation involves a comparison of the estimated recoverable amounts of non-financial assets to their carrying values. The estimated recoverable amounts may differ from actual recoverable amounts, and these differences may be significant and could have a material impact on the Company's financial position and results of operations.

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

**5. CASH AND CASH EQUIVALENTS**

	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Cash	2,081,866	1,548,547
Cash equivalents	2,350	2,931,318
	<b>2,084,216</b>	<b>4,479,865</b>

Cash equivalents at December 31, 2025 are comprised of high interest deposits bearing an interest rate of 1.80% as at December 31, 2025 (3.20% and 4.10% as at December 31, 2024).

**6. INVESTMENT PROPERTY – OUTFITTER**

Property and equipment of investment property – Outfitter are as follows:

	<b>BUILDINGS</b>	<b>EQUIPMENT AND FURNITURE</b>	<b>COMPUTER EQUIPMENT</b>	<b>TOTAL</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
<b>COST</b>				
AS AT DECEMBER 31, 2023	344,665	178,366	2,577	525,608
Acquisition	-	19,603	-	19,603
Derecognition of assets	-	(6,000)	-	(6,000)
AS AT DECEMBER 31, 2024	344,665	191,969	2,577	539,211
Acquisition	-	2,500	-	2,500
<b>AS AT DECEMBER 31, 2025</b>	<b>344,665</b>	<b>194,469</b>	<b>2,577</b>	<b>541,711</b>
<b>ACCUMULATED DEPRECIATION</b>				
AS AT DECEMBER 31, 2023	168,155	161,115	2,577	331,847
Depreciation	13,788	6,975	-	20,763
Derecognition of assets	-	(6,000)	-	(6,000)
AS AT DECEMBER 31, 2024	181,943	162,090	2,577	346,610
Depreciation	13,788	7,226	-	21,014
<b>AS AT DECEMBER 31, 2025</b>	<b>195,731</b>	<b>169,316</b>	<b>2,577</b>	<b>367,624</b>
<b>NET BOOK VALUE</b>				
AS AT DECEMBER 31, 2024	162,722	29,879	-	192,601
<b>AS AT DECEMBER 31, 2025</b>	<b>148,934</b>	<b>25,153</b>	<b>-</b>	<b>174,087</b>

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

The following table summarizes the information related to the net loss of investment property – Outfitter:

	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Outfitter income	43,244	84,178
<b>OPERATING EXPENSES</b>		
Management fees	54,842	73,041
Professional fees	-	3,787
Repair and maintenance	10,882	19,616
Supplies	20,427	20,301
Advertising, promotion, and travel	3,509	4,596
Travel to site and accommodation	8,943	6,107
Office expenses, taxes and licenses	13,664	12,424
Insurance	21,394	20,116
Interest and bank charges	226	(127)
Depreciation of property and equipment	21,014	20,763
Tax on investment property – outfitter	-	(4,577)
	154,901	176,047
<b>NET LOSS OF INVESTMENT PROPERTY – OUTFITTER</b>	<b>111,657</b>	<b>91,869</b>

**7. RIGHT-OF-USE ASSETS**

	<b>BUILDINGS</b>
	<b>\$</b>
<b>COST</b>	
AS AT DECEMBER 31, 2023	349,314
End of lease	(225,600)
<b>AS AT DECEMBER 31, 2024 AND 2025</b>	<b>123,714</b>
<b>ACCUMULATED DEPRECIATION</b>	
AS AT DECEMBER 31, 2023	229,223
Depreciation	25,831
End of lease	(225,600)
AS AT DECEMBER 31, 2024	29,454
Depreciation	23,565
<b>AS AT DECEMBER 31, 2025</b>	<b>53,019</b>
<b>NET BOOK VALUE</b>	
AS AT DECEMBER 31, 2024	94,260
<b>AS AT DECEMBER 31, 2025</b>	<b>70,695</b>

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

**8. PROPERTY AND EQUIPMENT**

	<b>TOOLS AND EQUIPMENT</b>	<b>COMPUTER EQUIPMENT</b>	<b>ROLLING EQUIPMENT</b>	<b>LAND</b>	<b>MINERAL PROPERTY UNDER DEVELOPMENT</b>	<b>TOTAL</b>
<b>COST</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
AS AT DECEMBER 31, 2023	19,673	16,817	37,635	1,096,415	61,855,024	63,025,564
Acquisition	2,070	5,238	-	-	133,572	140,880
Derecognition of assets	-	(4,812)	-	-	-	(4,812)
Mining tax credits reversal	-	-	-	-	4,515	4,515
AS AT DECEMBER 31, 2024	21,743	17,243	37,635	1,096,415	61,993,111	63,166,147
Acquisition	-	-	-	-	132,101	132,101
<b>AS AT DECEMBER 31, 2025</b>	<b>21,743</b>	<b>17,243</b>	<b>37,635</b>	<b>1,096,415</b>	<b>62,125,212</b>	<b>63,298,248</b>
<b>ACCUMULATED DEPRECIATION</b>						
AS AT DECEMBER 2023	14,128	12,729	17,867	-	-	44,724
Depreciation	1,357	6,021	4,704	-	-	12,082
Derecognition of assets	-	(4,812)	-	-	-	(4,812)
AS AT DECEMBER 31, 2024	15,485	13,938	22,571	-	-	51,994
Depreciation	1,564	(2,293)	4,704	-	-	3,975
<b>AS AT DECEMBER 31, 2025</b>	<b>17,049</b>	<b>11,645</b>	<b>27,275</b>	<b>-</b>	<b>-</b>	<b>55,969</b>
<b>NET BOOK VALUE</b>						
AS AT DECEMBER 31, 2024	6,258	3,305	15,064	1,096,415	61,993,111	63,114,153
<b>AS AT DECEMBER 31, 2025</b>	<b>4,694</b>	<b>5,598</b>	<b>10,360</b>	<b>1,096,415</b>	<b>62,125,212</b>	<b>63,242,279</b>

On December 31, 2024, the market capitalisation was lower than the book value of the Company and the Company completed in June 2024 a study on the construction of a purified phosphoric acid plant to transform phosphate rock concentrate that can be purchased on the market on long term contract basis and could eventually include rock concentrate from the Lac à Paul project. That was considered as indicators of impairment, among other facts and circumstances and, accordingly, the management performed an impairment assessment. The impairment assessment resulted in no impairment charge. No impairment indicators were identified in 2025.

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

**9. LEASE LIABILITIES**

	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
BALANCE – BEGINNING OF YEAR	107,644	132,074
Interests	2,901	9,955
New lease	-	-
Lease payments	(29,925)	(34,385)
<b>LEASE LIABILITIES – END OF YEAR</b>	<b>80,620</b>	<b>107,644</b>
Current portion	26,781	23,218
Non-current portion	53,839	84,426

**10. CREDIT LINE AND EMBEDDED DERIVATIVES**

The Company has non-revolving credit lines with Mercury Financing Corp. (“the Lender”) which were obtained to finance the development of the Lac a Paul project. As of May 12, 2016, the lines were fully drawn. The Lender holds a first ranking security over the Company’s Lac a Paul property claims, up to an aggregate amount of \$27 million. The wholly owned subsidiary, 9252-5880 Québec Inc., has guaranteed jointly and severally the credit lines. Furthermore, the Company is subject to restrictions related to the disposal of assets and equity issuance through financing. The combined credit lines have been extended in 2017, 2018, 2020 and 2021.

On March 17, 2021, the Company amended and extended its credit line until March 31, 2026. Since the amendment, the credit line bears interest at an annual rate equal to 8%, with all interest capitalized to the principal amount, to be paid annually in cash or in common shares of the Company using the volume weighted average price (“VWAP”) of the Company’s shares for a period of 1 year prior to the interest payment date. It was determined that the option of conversion of the interest using the VWAP is an embedded derivatives to be separated from the host contract.

In conjunction with the amended credit line, the Lender received 32 million non-transferable share purchase warrants, exercisable at a price of \$0.33 per warrant for a period of 5 years. These warrants are subject to a “warrant blocker” provision meaning the Lender’s holdings can only go above 19.9% of the issued and outstanding common shares of the Company in certain limited circumstances. An amount of \$8,412,413 was allocated to the fair value of the warrants, using the Black-Scholes pricing model. In connection with this extension, the Company also paid \$47,522 of transaction fees. These warrants were renounced by the Lender on February 25, 2026.

Since the terms of the extended credit facility were substantially different, the modification was considered as an extinguishment of the original credit line. The difference between the carrying value of the credit line extinguished and the new credit line was recognized in the year ended December 31, 2021, in the consolidated statement of income (loss) and comprehensive income (loss), through a gain of \$175,827. The Company used an effective interest rate of 33.7%.

The Company has undertaken to raise additional funds in the amount of \$3 million within the 1-year anniversary of the closing of the transaction, and every anniversary thereafter for the three subsequent

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

---

years, for total cumulative gross proceeds of \$12M. Should the Company not raise additional funds on a yearly and cumulative basis, the Company shall issue the Lender an additional 5M non-transferable share purchase warrants per year where a funding milestone has not been met (maximum of 20M non-transferable warrants). Each warrant will be exercisable at a price per share equal to the market price on the date such warrants must be issued by the Company and will expire on the date the amended credit facility expires. This requirement included in the debt agreement was determined to be an embedded derivative to be separated from the host contract and classified as a liability because it failed the fixed for fixed criteria per IAS 32.11. On March 31, 2025, 5M non-transferable share purchase warrants were granted to the Lender in connection with this clause. The fair value was estimated at \$52,851 using the Black-Scholes option pricing model. These warrants were renounced by the Lender on February 25, 2026.

In connection with the credit line, in August 2012, the Company granted the Lender of the credit line a royalty of \$1 per ton of phosphate concentrate sales from the Lac à Paul project. This royalty may be redeemed at any time through a lump-sum payment of \$9 million. In July 2013, the Company also granted the Lender of the credit line a royalty of \$0.25 per ton of phosphate concentrate sales from the Lac à Paul project that can be also redeemed any time through a lump-sum payment of \$2.25 million. These royalties will have to be redeemed by the Company for the same amount in the event of a change of control where at least 90% of the issued and outstanding shares of the Company are acquired, purchased, or held by a third party, either through a tender offer or other transaction with the same result. It was determined that this clause does not constitute an embedded derivative because of the non-financial variable specific to the Company and therefore the cash flows from the buy back of the production fees had to be included in the amortized cost of the host contract.

For the first 4 years of the amended credit facility, and as amended on March 28, 2024, in the event the Company has not repaid the credit line in full and the Lender remains the creditor of the Company in relation to such credit line, the Company shall grant the Lender an additional annual production fee of \$0.25/tonne, which may be bought back by the Company for \$2.25M, for a maximum annual additional production fee of \$0.75/tonne (which may be bought back by the Company for a total amount of \$6.75M). It was determined that this clause does not constitute an embedded derivative because of the non-financial variable specific to the Company and therefore the cash flows from the buy back of the production fees had to be included in the amortized cost of the host contract.

The Company has the option to reimburse the credit line before its maturity without any penalty. This was considered an embedded derivative to be separated from the host contract and it was determined that the fair value of that option was nil.

On March 31, 2025, the Company opted to issue 10,824,601 common shares at a price of \$0.155 per share, in lieu of cash, as its annual interest payment to the Lender due on March 31, 2025 (6,080,939 common shares at a price of \$0.27 per share in lieu of cash as at March 31, 2024). The carrying value of the interest payable and of the corresponding embedded derivative – interest conversion option were then transferred to capital stock.

In December 2025, the Company revised timing of the cash flows from the production fees buy-back, which reduced the financial costs on the credit line. As at December 31, 2025, the Company estimates that the buyback will occur in 2032.

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

On March 31, 2026, the Company amended and extended its credit facility until September 30, 2027 (Note 21).

YEAR ENDED DECEMBER 31, 2025	HOST	EMBEDDED DERIVATIVES		TOTAL
		INTEREST CONVERSION OPTION	SUPPLEMENTAL WARRANTS	
	\$	\$	\$	\$
BALANCE – BEGINNING OF YEAR	31,453,461	(280,357)	48,254	31,221,358
Interest paid in shares	(1,958,170)	280,357	-	(1,677,813)
Change in fair value of derivative	-	-	4,597	4,597
Warrants issued	-	-	(52,851)	(52,851)
Change in estimate	(14,733,690)	-	-	(14,733,690)
Capitalized interest and accretion	11,485,484	-	-	11,485,484
<b>BALANCE – END OF YEAR</b>	<b>26,247,085</b>	<b>-</b>	<b>-</b>	<b>26,247,085</b>
Current portion	25,952,462	-	-	25,952,462
Non-current portion	294,623	-	-	294,623

YEAR ENDED DECEMBER 31, 2024	HOST	EMBEDDED DERIVATIVES		TOTAL
		INTEREST CONVERSION OPTION	SUPPLEMENTAL WARRANTS	
	\$	\$	\$	\$
BALANCE – BEGINNING OF YEAR	24,565,877	(456,148)	24,519	24,134,248
Interest paid in shares	(1,963,535)	321,682	-	(1,641,853)
Change in fair value of derivative	-	(145,891)	23,735	(122,156)
Capitalized interest and accretion	8,851,119	-	-	8,851,119
<b>BALANCE – END OF YEAR</b>	<b>31,453,461</b>	<b>(280,357)</b>	<b>48,254</b>	<b>31,221,358</b>
Current portion	1,958,170	(280,357)	-	1,677,813
Non-current portion	29,495,291	-	48,254	29,543,545

## 11. CONVERTIBLE DEBENTURE

On October 10, 2024, the Company issued a convertible debenture in the principal of \$3,808,269, that matures on October 10, 2027 and bears interest at 9.5% per annum that are added to the principal amount.

The Holder has the option, at any time and subject to customary adjustments, to convert (i) the principal amount of the convertible debenture at a price of \$0.35 per common share, and (ii) the accrued interest thereon at a price per share equal to the greater of (a) \$0.35 and (b) the market price at the time the accrued interest is converted, as determined in accordance with the rules of the TSX Venture Exchange.

The conversion price of the convertible debenture is subject to adjustments, including in the event that the Company issues a convertible debenture or other similar debt-like instrument convertible into common

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

shares to any person (other than the debenture Holder or its affiliates) pursuant to a transaction that is not a common share reorganization, rights offering or capital reorganization (a "Third Party Debenture Issuance"), in any such case at an effective conversion or exercise price (net of all fees and commissions associated with such subscription) (the "Third Party Debenture Issuance Price") that is less than the conversion price applicable at the time of such issuance, in which case, upon closing of such Third Party Debenture Issuance: (i) the conversion price for the principal amount shall automatically be adjusted downwards to the greater of: (a) the Third Party Debenture Issuance Price; and (b) \$0.19, and (ii) the conversion price for the accrued interest shall be equal to the market price at the time such amounts are converted into common shares, as determined in accordance with the rules of the TSX Venture Exchange, subject to the application of Policy 4.3 – Shares for Debt of the TSX Venture Exchange. It was determined that the conversion option is an embedded derivative to be separated from the host contract and classified as a liability because it failed the fixed for fixed criteria per IAS 32.11. Also, because the Holder can convert the debenture at any time, per IAS 1 *Presentation of financial statements*, the convertible debt is classified as a short-term liability.

In some circumstances of common share reorganization, rights offering, special distribution and capital reorganization, the conversion price for the principal amount can be modified. It was determined that this was an embedded derivative classified as a liability to be separated from the host contract.

In the event of a change of control or a project transfer, the Holder has the right to require the Company to redeem the debenture at a price equal to (i) 130% of the original principal amount of the debenture, plus (ii) all accrued and unpaid interest. This was considered as an embedded derivative classified as a liability to be separated from the host contract.

No common shares of the Company shall be issued to the Holder if, as a result of such issuance, the Holder would beneficially own or exercise control or direction over 9.99% that would be issued and outstanding immediately after giving effect of such issuance. The Holder may, at its sole discretion, increase the ownership cap to 19.99% of the common shares that would be issued and outstanding immediately after any issuance. This clause does not constitute an embedded derivative but has to be considered when evaluating the fair value of the conversion option.

According to IFRS 9.B4.3.4, all the embedded derivatives in the single hybrid contract were treated as a single compound embedded derivative. The Company used an effective interest rate of 16.67%.

Upon the Holder reaching an ownership of at least 3.0% of the issued and outstanding common shares of the Company (either through conversion, open market purchase or otherwise), the Company will enter into an investor rights agreement with the Holder that will provide customary participation and top-up rights and a board nomination right.

<b>YEAR ENDED DECEMBER 31, 2025</b>	<b>HOST</b>	<b>EMBEDDED DERIVATIVES</b>	<b>TOTAL</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
BALANCE – BEGINNING OF YEAR	2,822,062	510,850	3,332,912
Change in fair value of derivative	-	140,692	140,692
Capitalized interest and accretion	666,496	-	666,496
<b>BALANCE – END OF YEAR</b>	<b>3,488,558</b>	<b>651,542</b>	<b>4,140,100</b>

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

<b>YEAR ENDED DECEMBER 31, 2024</b>	<b>HOST</b>	<b>EMBEDDED DERIVATIVES</b>	<b>TOTAL</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
BALANCE – BEGINNING OF YEAR	-	-	-
New debenture	2,871,123	937,146	3,808,269
Issuance costs	(150,942)	-	(150,942)
Change in fair value of derivative	-	(426,296)	(426,296)
Capitalized interest and accretion	101,881	-	101,881
<b>BALANCE – END OF YEAR</b>	<b>2,822,062</b>	<b>510,850</b>	<b>3,332,912</b>

**12. FINANCE COSTS (INCOME)**

	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Financial expenses on credit line	(3,248,206)	8,851,119
Financial expenses on convertible debenture	666,496	101,881
Change in fair value of embedded derivatives – credit line	4,597	(122,156)
Change in fair value of embedded derivatives – convertible debenture	140,692	(426,296)
Interest expense on lease liabilities	2,901	9,955
Interest income	(98,711)	(102,335)
	<b>(2,532,231)</b>	<b>8,312,168</b>

**13. CAPITAL STOCK**

**AUTHORIZED**

Unlimited number of common shares without par value.

Unlimited number of preferred shares, without par value, issuable in series: Series A includes 500,000 preferred shares, non-voting, non-cumulative dividend of 8% redeemable by the Company at the amount paid in.

**YEAR ENDED DECEMBER 31, 2025**

On March 31, 2025, the Company issued 10,824,601 common shares at a price of \$0.155 per share, in lieu of cash, as its annual interest payment relating to the credit line as at March 31, 2025 (Note 10).

**YEAR ENDED DECEMBER 31, 2024**

On April 1st, 2024, the Company issued 6,080,939 common shares at a price of \$0.27 per share, in lieu of cash, as its annual interest payment relating to the credit line as at March 31, 2024 (Note 10).

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

**14. STOCK OPTIONS, WARRANTS AND OPTIONS GRANTED TO BROKERS**

**STOCK OPTIONS**

The shareholders of the Company initially approved on June 25, 2013, a stock option plan, amended on September 26, 2025 (the “plan”) whereby the Board of Directors may grant stock options of the Company to directors, officers, employees and suppliers. The terms of stock options are determined by the Board of Directors.

The stock options granted to directors and employees vest on a basis of 33% every year on a three-year period from the date of grant and options to consultants vest on a basis of 25% every three months, starting three months after the grant date.

Stock options expire no later than ten years after being granted. The exercise price of each share purchase option is determined by the Board of Directors and may not be lower than the market price of the common shares at the time of grant.

The plan provides that (i) the maximum number of common shares in the capital of the Company that may be reserved for issuance under the plan shall be equal to 10% common shares; (ii) the maximum number of common shares which may be reserved for issuance to an employee, officer or director may not exceed 5% of the outstanding common shares at the time of grant; and (iii) the maximum number of shares which may be reserved for issuance to consultants and investors representative may not exceed 2% of the outstanding common shares at the time of grant.

Any share purchase option is settled in shares in accordance with Company policies.

The Company currently estimates the volatility of its common shares based on historical data from the Company.

During 2025, 1,470,000 stock options were granted to a consultant and a management member pursuant to the plan, having a total fair value of \$158,820 (\$113,104 in 2024). The options, when granted, are accounted for at their fair value determined by the Black-Scholes option pricing model based on the vesting period and on the following weighted average assumptions:

	<b>2025</b>	<b>2024</b>
Weighted average price of share at time of grant	\$0.16	\$0.26
Weighted average exercise price	\$0.16	\$0.26
Weighted average risk-free interest rate	3.16%	3.88%
Weighted average expected volatility	68%	69%
Weighted average expected life	8.37 years	8.15 years
Weighted average expected dividend yield	0%	0%
Weighted average fair value of options granted	\$0.11	\$0.17

The fair value of the share options is recognized as compensation expense over the vesting period. In 2025, the total share-based compensation amounted to \$182,754 (\$284,361 in 2024).

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

Changes in the Company stock options were as follows:

	2025		2024	
	NUMBER	WEIGHTED AVERAGE EXERCISE PRICE	NUMBER	WEIGHTED AVERAGE EXERCISE PRICE
		\$		\$
<b>BALANCE – BEGINNING</b>	7,834,667	0.44	8,274,667	0.50
Granted	1,470,000	0.16	650,000	0.26
Expired	(1,160,000)	0.63	(1,015,000)	0.80
Forfeited	-	-	(75,000)	0.28
<b>BALANCE – END</b>	<b>8,144,667</b>	<b>0.37</b>	<b>7,834,667</b>	<b>0.44</b>
EXERCISABLE - END	6,973,000	0.40	6,551,334	0.47

The following table summarizes the information relating to the stock options outstanding under the plan as at December 31, 2025:

EXERCISE PRICE RANGE	WEIGHTED AVERAGE EXERCISE PRICE	WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE	OPTIONS OUTSTANDING 2025	OPTIONS OUTSTANDING 2024
\$	\$	Years		
0.18 – 0.28	0.20	7.07	3,413,000	1,943,000
0.29 – 0.44	0.37	6.78	2,296,667	2,396,667
0.45 – 0.63	0.54	5.30	1,930,000	2,580,000
0.63 – 1.30	0.78	0.89	505,000	915,000
			8,144,667	7,834,667
		<b>EXERCISABLE</b>	6,973,000	6,551,334

**WARRANTS**

Changes in the Company warrants were as follows:

	2025		2024	
	NUMBER	WEIGHTED AVERAGE EXERCISE PRICE	NUMBER	WEIGHTED AVERAGE EXERCISE PRICE
		\$		\$
<b>BALANCE – BEGINNING</b>	32,000,000	0.33	33,478,278	0.34
Granted	5,000,000	0.33	-	-
Expired	-	-	(1,478,278)	0.55
<b>BALANCE – END</b>	<b>37,000,000</b>	<b>0.33</b>	<b>32,000,000</b>	<b>0.33</b>

During 2025, 5,000,000 warrants were granted in relation with the credit line having a total fair value of \$52,851 (\$Nil in 2024). The warrants, when granted, are accounted for at their fair value determined by the Black-Scholes pricing model based on the following assumptions:

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

	<b>2025</b>
Weighted average price of share at time of grant	\$0.155
Weighted average exercise price	\$0.33
Weighted average risk-free interest rate	2.60%
Weighted average expected volatility	68%
Weighted average expected life	1 year
Weighted average expected dividend yield	0%
Weighted average fair value of options granted	\$0.0106

The following table summarizes the information relating to the outstanding warrants as at December 31, 2025:

<b>EXERCISE PRICE</b>	<b>EXPIRY DATE</b>	<b>WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE</b>	<b>WARRANTS OUTSTANDING 2025</b>	<b>WARRANTS OUTSTANDING 2024</b>
<b>\$</b>		<b>Years</b>		
0,33	2026-03-31	0.25	37,000,000	32,000,000

On February 25, 2026, the holder renounced to all the outstanding warrants.

**15. DEFERRED TAXES**

The major components of deferred income tax expense are as follows:

	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Deferred tax expense relating to the origination and reversal of temporary differences	-	(4,515)
<b>TOTAL DEFERRED INCOME TAX EXPENSE</b>	<b>-</b>	<b>(4,515)</b>

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

The Company's income tax provision consists of the following:

	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Income (loss) before income taxes	42,177	(10,995,234)
Income tax computed at Canadian statutory rate of 26.5% in 2023 (26.5% in 2022)	11,177	(2,913,737)
Non-deductible expenses	49,817	77,610
Unrecognized tax benefits	(91,904)	2,813,220
Quebec mining duty tax (recovery)	-	(4,515)
Tax on investment property – outfitter	29,589	26,333
Other	1,321	(3,426)
<b>Income tax expense (recovery)</b>	<b>-</b>	<b>(4,515)</b>
Income tax expense		
Deferred	-	(4,515)

The analysis of deferred income tax assets and liabilities as at December 31, 2025 and 2024 is as follows:

	<b>2024</b>	<b>CONSOLIDATED</b>	<b>2025</b>
		<b>STATEMENT OF</b>	
		<b>INCOME (LOSS)</b>	
	<b>\$</b>	<b>\$</b>	<b>\$</b>
<b>DEFERRED INCOME TAX ASSETS</b>			
Exploration and evaluation assets	5,772,877	39,773	5,812,650
Non-capital losses carried forward	9,773,482	143	9,773,625
	15,546,359	39,916	15,586,275
<b>DEFERRED INCOME TAX LIABILITIES</b>			
Property and equipment	(15,546,359)	(39,916)	(15,586,275)
Mining duties tax	(3,702,929)	-	(3,702,929)
	(19,249,288)	(39,916)	(19,289,204)
<b>TOTAL DEFERRED INCOME TAX LIABILITIES</b>	<b>(3,702,929)</b>	<b>-</b>	<b>(3,702,929)</b>

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

	2023	CONSOLIDATED STATEMENT OF INCOME (LOSS)	2024
	\$	\$	\$
<b>DEFERRED INCOME TAX ASSETS</b>			
Exploration and evaluation assets	6,359,034	(586,157)	5,772,877
Non-capital losses carried forward	9,766,329	7,153	9,773,482
	16,125,363	(579,004)	15,546,359
<b>DEFERRED INCOME TAX LIABILITIES</b>			
Property and equipment	(15,514,164)	(32,195)	(15,546,359)
Financial instrument	(611,199)	611,199	-
Mining duties tax	(3,707,444)	4,515	(3,702,929)
Tax on investment property – outfitter	(4,577)	4,577	-
	(19,837,384)	588,096	(19,249,288)
<b>TOTAL DEFERRED INCOME TAX LIABILITIES</b>	(3,712,021)	9,092	(3,702,929)

The ability to realize the tax benefits is dependent upon several factors, including the future profitability of operations. Deferred tax assets are recognized only to the extent that it is probable that sufficient taxable profits will be available to allow the asset to be recovered. Accordingly, some deferred tax assets have not been recognized.

As at December 31, 2025, the Company had unrecognized deferred tax assets as follows:

	2025	2024
	\$	\$
Non-capital losses carried forward	13,112,414	11,893,414
Convertible debenture and credit line	46,514	1,155,364
Income tax benefit of mining duties	981,276	981,276
Share issue costs	29,478	73,760
Other assets	15,136	16,052
	14,184,818	14,119,866

As at December 31, 2025, the Company had accumulated non-capital losses of \$90,065,348 for Federal tax purposes and \$83,902,484 for Provincial tax purposes (\$85,453,011 and \$79,214,641 respectively as at December 31, 2024) which can be used to reduce taxable income between 2026 and 2045.

The Company has also accumulated capital losses for tax purposes in Quebec of approximately \$217,490 (\$217,490 in 2024), and these losses can be carried forward indefinitely.

The Company is subject to federal and provincial income taxes and provincial mining taxes. Tax laws are complex and can be subject to different interpretations. The Company has prepared its tax provision based on the interpretation of tax laws which it believes represents the probable outcome. The Company may be required to change its provision for income taxes if the tax authorities ultimately are not in agreement with

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

the Company's interpretation.

**16. RELATED PARTY TRANSACTIONS**

The table below shows related party transactions and balances payable for each of the Company's related parties:

	<b>2025</b>	<b>2024</b>
	\$	\$
<b>KEY MANAGEMENT COMPENSATION</b> <sup>(1)</sup>		
Share-based compensation	166,249	264,192
Management fees	29,980	-
Salaries and benefits <sup>(2)</sup>	737,131	682,507
<b>TOTAL COMPENSATION</b>	<b>933,361</b>	<b>946,699</b>
Balance included in accounts payable and accrued liabilities	5,492	-

(1) The key management is composed of the Chief executive officer, Chief Financial Officer, Chief Operating Officer, Head of Strategic & Business Initiatives (2024-President and Directors).

(2) Salaries and benefits capitalized to property and equipment amount to \$38,549 (\$18,944 in 2024).

The agreements with the Company's key executives and key employees provide for payments on termination of employment following a change of control of \$705,000.

**17. COMMITMENTS**

- a) The Company has granted to a third party a 2.25% royalty on the net smelter return ("NSR") over the Lac à Paul project. The royalty may be redeemed at any time through a lump-sum payment of \$2 million.
- b) The Company may grant contracts in relation to the development of the Lac à Paul project. The total committed as at December 31, 2025 is \$98,600 (\$290,153 as at December 31, 2024). These contracts usually do not have termination dates and disbursements are made in accordance with the project's milestones.

**18. CONTINGENCIES**

In the normal course of operations, the Company is exposed to events that could give rise to contingent liabilities. As at the date of issue of the consolidated financial statements, the Company was not aware of any significant events that would have a material effect on its consolidated financial statements.

**19. FINANCIAL INSTRUMENTS AND FINANCIAL RISKS**

**FINANCIAL RISKS**

The Company has exposure to various financial risks, such as credit risk, liquidity risk, interest rate risk, equity risk, currency risk and fair value risk from its use of financial instruments.

**CREDIT RISK**

The Company's credit risk is primarily attributable to cash and cash equivalents and receivables and other

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

current assets. Cash and cash equivalents are deposited in Canadian chartered bank accounts or invested in a diversified manner in securities having an investment-grade rating (AA-), from which management believes the risk of loss to be minimal. Receivables and other current assets mainly consist of interest receivable from Canadian chartered banks. Management believes that the credit risk concentration with respect to financial instruments included in amounts receivable is minimal.

**LIQUIDITY RISK**

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected if the Company's access to the capital market is hindered, whether because of a downturn in stock market conditions generally or related to matters specific to the Company. The Company generates cash flows primarily from its financing activities. As at December 31, 2025, the Company had cash and cash equivalents of \$2,084,216 (\$4,479,865 as at December 31, 2024) to settle current liabilities of \$30,365,701 (\$5,288,806 as at December 31, 2024), of which \$4,140,100 is related to the convertible debenture that is due in October 2027 and 25,952,462 is related to the credit line that was amended after December 31, 2025 (Note 21). The Company regularly evaluates its cash position to ensure preservation and security of capital as well as maintenance of liquidity (Refer to Note 1 for the use of the going concern assumption).

The following are the contractual maturities of financial liabilities and other liabilities, including interest where applicable as at December 31, 2025:

	<b>CARRYING</b>	<b>CONTRACTUAL</b>				<b>2029 AND</b>
	<b>AMOUNT</b>	<b>CASH FLOWS</b>	<b>2026</b>	<b>2027</b>	<b>2028</b>	<b>ONWARD</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
Accounts payable and accrued liabilities	246,358	246,358	246,358	-	-	-
Lease liabilities	80,620	93,654	30,321	30,400	30,400	2,533
Convertible debenture	4,140,100	5,000,000	-	5,000,000	-	-
Credit line (host)	26,247,085	44,435,298	26,435,298	-	-	18,000,000

**INTEREST RATE RISK**

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Financial liabilities are not exposed to interest rate risk as they are non-interest bearing or bear interest at a fixed rate.

**CURRENCY RISK**

Foreign currency risk is the risk that the Company's financial performance could be affected by fluctuations in the exchange rates between currencies. Some of the Company's expenditures are denominated in U.S. dollars and the Company holds insignificant balances in cash denominated in U.S. dollars. The impact on of an increase or decrease in foreign currencies would not be material.

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Payables in US dollars	30,000	30,000
Canadian dollar equivalent	41,070	43,151
Payables in GBP	25,000	25,000
Canadian dollar equivalent	46,173	45,183

**FAIR VALUE RISK**

The Company defines the fair value hierarchy under which its financial instruments are valued as follows: level 1 includes unadjusted quoted prices in active markets for identical assets or liabilities; level 2 includes inputs other than quoted prices in level 1 that are observable for assets or liabilities, either directly or indirectly; and level 3 includes inputs for the asset or liability that are not based on observable market data. There was no transfer of hierarchy level during the years ended December 31, 2025, and 2024.

The carrying value of cash and cash equivalents, receivables and other current assets, accounts payable and accrued liabilities are considered to be a reasonable approximation of their fair value because of the short-term maturity and contractual terms of these instruments.

The fair value of the credit line and the convertible debenture is based on discounted cash flows and is not materially different from their carrying value because there was no material change in the assumptions used for fair value determination at inception. Therefore, their principal amounts approximate their fair value.

The embedded derivative – interest conversion option on the credit line is classified as a level 3 instrument. An increase/decrease of the expected share price and expected VWAP used of 10% would lead to a variation in the fair value as at December 31, 2025 of \$Nil (\$Nil as at December 31, 2024).

The embedded derivatives on the convertible debenture are classified as a level 3 instrument. A, increase of 10% in the volatility and a 10% change in the probability determined for each embedded derivative, the main non-observable inputs used in the model, would lead to a variation in the fair value as at December 31, 2024 of \$97,000 (\$86,000 as at December 31, 2024).

**20. POLICIES AND PROCESSES FOR MANAGING CAPITAL**

As at December 31, 2025, the capital of the Company consists of equity amounting to \$31,439,235 (\$29,846,828 in 2024) and debts of \$30,387,185 (\$34,554,270 in 2024). The Company's capital management objective is to have sufficient capital to be able to meet its mining development plan and permitting to ensure the growth of its activities. It also has the objective to have sufficient cash to finance the investing activities and the working capital requirements. The variation of capital components is explained in the consolidated statements of changes in equity.

There were no significant changes in the Company's approach to capital management during the year ended December 31, 2025.

**ARIANNE PHOSPHATE INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(IN CANADIAN DOLLARS)

---

**21. SUBSEQUENT EVENTS**

On March 31, 2026, the Company and the Lender signed the executed an amended and restated credit agreement (Note 10). The secured credit facility under the Amended and Restated Credit Agreement will mature on September 30, 2027. The Loan will continue to bear interest at an annual rate of 8%, with all interest payable at maturity.

In connection with the Transaction:

- the Company issued 7,539,515 common shares to the Lender representing accrued interest on the Loan up to March 31, 2026 (the "Closing Date);
- the Company issued 10,000,000 common shares to the Lender. The Lender agreed to the following voluntary hold periods: 5,000,000 shares are subject to a voluntary hold period of six months from the Closing Date; and 5,000,000 shares are subject to a voluntary hold period of nine months from the Closing Date (collectively, the "Voluntary Hold Period"). In the event the Company completes an equity financing following the Closing Date, the Voluntary Hold Period shall be reduced to the lesser of (a) the period of time remaining under the Voluntary Hold Period, and (b) the regulatory hold period, if any, applicable to the securities issued by the Company under such equity financing. Furthermore, the Voluntary Hold Period shall automatically terminate in the event of a merger, amalgamation, acquisition, disposition, arrangement or other business combination transaction involving the Company (a "Business Combination Transaction");
- the Company issued 25,000,000 common share purchase warrants (the "2026 Warrants") to the Lender entitling the Lender to acquire the same number of common shares at a price of \$0.28 per share until September 30, 2027. Furthermore, the Lender shall not be entitled to exercise such aggregate number of 2026 Warrants which would result in it holding, following such exercise, on a partially-diluted basis, more than 19.9% of the issued and outstanding Common Shares, subject to certain conditions. The Lender shall nevertheless be entitled to exercise the 2026 Warrants without the limitations of these warrant exercise restrictions applying in the event of a Business Combination Transaction;
- the Company agreed to pay to the Lender an additional production fee of \$0.25 per metric ton of phosphate concentrate sales for the life of the project, including any non-arm's-length sales or in connection with any non-arm's-length transformation of such phosphate concentrate, which can be repurchased at any time for a lump sum payment of \$2.25 million. Should the Company fail to reimburse the Loan in full on or before March 31, 2027, the Company agreed to pay to the Lender an additional production fee of \$0.25 per metric ton of phosphate concentrate sales, including any non-arm's-length sales or in connection with any non-arm's-length transformation of such phosphate concentrate, which additional production fee can be repurchased at any time for a lump sum payment of \$2.25 million.

The Company has yet to determine the impact of this transaction.